The scientific advancement in this is due to the incorporation of several tools that allow for the study of lipids at a omic perspective, as well for the integration of such knowledge to a knowledge of cell signaling and population data, which has allowed for the progress concerning the identification of new biomarkers and new therapeutic targets.
Indeed, over the next years, there will probably be more pieces available to this network of interdisciplinary knowledge that goes beyond the from bench to bedside limitations. Endothelial cell metabolism: a novel player in atherosclerosis? Basic principles and therapeutic opportunities. Endothelial cell dysfunction and the pathobiology of atherosclerosis. Circ Res. Worldwide trends in body-mass index, underweight, overweight, and obesity from to a pooled analysis of population-based measurement studies in Cardiovascular and metabolic heterogeneity of obesity: clinical challenges and implications for management.
Obesity and cardiovascular disease: friend or foe? Eur Heart J. Body fat distribution and incident cardiovascular disease in obese adults. J Am Coll Cardiol.
Body fat distribution and risk of cardiovascular disease: an update. Impact of obesity on total and cardiovascular mortality: fat or fiction? Nat Rev Cardiol. Vascular complications of diabetes: mechanisms of injury and protective factors. Cell Metab. Selective insulin resistance and the development of cardiovascular diseases in diabetes: the Edwin Bierman Award Lecture.
Central role of metabolism in endothelial cell function and vascular disease. Physiology Bethesda. Endothelial cell metabolism in normal and diseased vasculature. Endothelial mitochondria: less respiration, more integration. Pflugers Arch.
A lactate-induced response to hypoxia. Metabolism of exogenous substrates by coronary endothelial cells in culture. J Mol Cell Cardiol. Acute regulation of fatty acid oxidation and amp-activated protein kinase in human umbilical vein endothelial cells. Bastin J. Endothelial cell metabolism.
Physiol Rev. Fatty acid carbon is essential for dNTP synthesis in endothelial cells. Lipids and the endothelium: bidirectional interactions. Curr Atheroscler Rep. FOXO1 couples metabolic activity and growth state in the vascular endothelium. Elevated circulating free fatty acid levels impair endothelium-dependent vasodilation. J Clin Invest. Theodorou K, Boon RA.
checkout.midtrans.com/alaqus-dating-gay.php Endothelial cell metabolism in atherosclerosis. Front Cell Dev Biol. Implications for the syndrome of insulin resistance. High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C: dependent activation of NAD P H oxidase in cultured vascular cells.
Endothelial acyl-CoA synthetase 1 is not required for inflammatory and apoptotic effects of a saturated fatty acid-rich environment. Arterioscler Thromb Vasc Biol. Effects of gastric bypass surgery followed by supervised physical training on inflammation and endothelial function: a randomized controlled trial. Fatty acid metabolic remodeling during type 2 diabetes remission after bariatric surgery. Metabolically healthy obese and incident cardiovascular disease events among 3. The long-term prognosis of cardiovascular disease and all-cause mortality for metabolically healthy obesity: a systematic review and meta-analysis.
J Epidemiol Community Health. Are metabolically healthy overweight and obesity benign conditions? A systematic review and meta-analysis. Ann Intern Med.
Combined effect of obesity and cardio-metabolic abnormality on the risk of cardiovascular disease: a meta-analysis of prospective cohort studies. Int J Cardiol.
Pericytes have been implicated in providing survival signal to the developing blood vessels overcoming the inhibition of VEGF leading to ongoing angiogenesis within the macula. Monoclonal antibodies blocking VEGF and inhibitors of tyrosine kinase receptors have become a mainstay in cancer regimes for multiple indications Anne-Theres Henze, Massimiliano Mazzone. Aging also influences endothelial cells and causes a progressive deterioration of their function. Cell — Furthermore, Qian et al.
Impact of body mass index on left ventricular diastolic dysfunction. Impact of diabetes and increasing body mass index category on left ventricular systolic and diastolic function. J Am Soc Echocardiogr. Correlates of echocardiographic indices of cardiac remodeling over the adult life course: longitudinal observations from the Framingham Heart Study. Overweight and obesity impair left ventricular systolic function as measured by left ventricular ejection fraction and global longitudinal strain.
Cardiovasc Diabetol. Serum levels of advanced glycation end products are associated with left ventricular diastolic function in patients with type 1 diabetes. Diabetes Care. Metabolically-healthy obesity and coronary artery calcification. Risk of ischemic stroke in metabolically healthy obesity: a nationwide population-based study. PLoS One. Zelniker TA, Braunwald E.
Cardiac and renal effects of sodium-glucose co-transporter 2 inhibitors in diabetes: JACC state-of-the-art review. Clinical implications of current cardiovascular outcome trials with sodium glucose cotransporter-2 SGLT2 inhibitors.
Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. Canagliflozin and cardiovascular and renal events in type 2 diabetes. Lower risk of heart failure and death in patients initiated on sodium-glucose cotransporter-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL Study Comparative effectiveness of cardiovascular outcomes in new users of sodium-glucose cotransporter-2 inhibitors.
Dipeptidyl peptidase-4 inhibitors moderate the risk of genitourinary tract infections associated with sodium-glucose co-transporter-2 inhibitors. Diabetes Obes Metab. Benefits and harms of sodium-glucose co-transporter 2 inhibitors in patients with type 2 diabetes: a systematic review and meta-analysis.
Cardiovascular safety, long-term noncardiovascular safety, and efficacy of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes mellitus: a systemic review and meta-analysis with trial sequential analysis. J Am Heart Assoc. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin.
J Clin Endocrinol Metab. Energy balance after sodium-glucose cotransporter 2 inhibition. SGLT2 Inhibition by empagliflozin promotes fat utilization and browning and attenuates inflammation and insulin resistance by polarizing m2 macrophages in diet-induced obese mice.
This book surveys healthy and diseased vascular systems in a multitude of model organisms and systems. It explores a plethora of functions, characteristics, and. Vascular endothelial growth factor signaling in development and disease. Karaman S(1), Leppänen VM(1), Alitalo K(2). Author information.
Nat Rev Endocrinol. Effectiveness of dapagliflozin on vascular endothelial function and glycemic control in patients with early-stage type 2 diabetes mellitus: DEFENCE study.
Effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on blood pressure and markers of arterial stiffness in patients with type 2 diabetes mellitus: a post hoc analysis. The effects of sodium-glucose cotransporter 2 inhibitors on sympathetic nervous activity. Front Endocrinol Lausanne. Antihyperglycemic agents as novel natriuretic therapies in diabetic kidney disease. Am J Physiol Renal Physiol. Cardiovasc Drugs Ther.